Physician profile
Anson Hsieh
NPI 1316940596
$14,761.99
in general payments reported to CMS, 2019-2025
53 companies · $1,795 in 2025
The $1,795 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $961 · 2020: $1,763 · 2021: $2,608 · 2022: $2,360 · 2023: $2,832 · 2024: $2,445 · 2025: $1,795.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,063 · Education: $8.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,062.79 |
| Education | $8.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,843.02 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,135.00 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $1,133.86 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $1,070.50 | 2019-2025 | Repatha, Otezla, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,028.92 | 2019-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $953.39 | 2019-2025 | |
| Novo Nordisk INC | $785.37 | 2019-2024 | Wegovy, Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $710.62 | 2021-2025 | |
| Lilly USA, LLC | $669.58 | 2019-2024 | Mounjaro, Jardiance, Emgality |
| Pfizer INC. | $640.59 | 2019-2025 | |
| Amarin Pharma, INC. | $397.55 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $379.37 | 2019-2025 | Jardiance |
| Astellas Pharma US INC | $379.10 | 2019-2025 | Veozah |
| Merck Sharp & Dohme LLC | $343.21 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Janssen Pharmaceuticals, INC | $333.60 | 2019-2021 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anson Hsieh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.